Mabvax Finds $500K

San Diego-based Mabvax Pharmaceuticals, which is developing vaccines and human antibodies targeted at treating cancer, has gained $500,000 out of a $4M funding round, according to a regulatory filing from the firm. Mabvax had previously raised $8M in Series A funds from GBP Capital in February of 2008. No details on the new round have been released by the firm. More information »